National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Posted on

Funding to Support Research and Expanded Access of Investigational Drug in ALS SALT LAKE CITY, Oct. 05, 2023 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological […]

Read More

Owlet Commits Critical Support To Parents and Researchers On A Mission To End SIDS

LEHI, Utah–(BUSINESS WIRE)– Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), a pioneer of smart baby monitoring, is on a mission to raise critical funds for research that could bring an end to sudden infant death syndrome (SIDS). Owlet is partnering in this effort with Dr. Carmel Harrington, Honorary Research Fellow at Sydney Children’s Hospital […]

Read More

bioMérieux submits Dual 510(k) and CLIA-waiver application to FDA for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel

Marcy-l’Étoile (France), September 22nd, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, has submitted the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel to U.S. Food and Drug Administration (FDA) for a dual 510(k) clearance and CLIA1-waiver. This panel is already CE-marked (IVDD2). […]

Read More

Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only test SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in […]

Read More

Myriad Genetics Issues 2022 Environmental, Social and Governance Report

SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its second annual Environmental, Social and Governance report, highlighting key efforts that reflect its commitment to conduct operations as a responsible, equitable and sustainable partner in the healthcare industry. “At Myriad, […]

Read More